Actionable news
All posts from Actionable news
Actionable news in FPRX: Five Prime Therapeutics, Inc.,

Endonovo Therapeutics Receives USPTO Notice of Allowance for Patent Covering Production of Biomolecules From Adult Stem Cells

Press Release

LOS ANGELES, CA, Mar 30, 2016 (Marketwired via COMTEX) -- Endonovo Therapeutics, Inc. (otcqb:ENDV) ("Endonovo" or the "Company"), an innovative biotechnology company developing bioelectronics-based products and therapies for regenerative medicine, announced today it has received a Notice of Allowance from the U.S. Patent and Trademark Office for a patent application entitled "Biological Molecules Produced by Electromagnetically Stimulating Living Mammalian Cells."

The patent application covers the production of biological molecules, including growth factors and cytokines in adult stem cells using the Company's proprietary technologies. This Notice of Allowance concludes substantive examination of the patent application and is expected to result in the issuance of a U.S. patent in the near future.

The Company has added this technology to its patent licensing program as it begins to pursue potential revenue producing applications of its portfolio of intellectual property.

Endonovo Chairman and CEO, Alan Collier commented, "we are excited about the issuance of this patent covering the production of biological molecules from adult stem cells, which can be used to produce human proteins." Conventional methods of protein production include recombinant techniques used with bacteria or CHO cells.

According to Thomson Reuters, the biologics sector is...